The stock of NewLink Genetics Corporation (NASDAQ:NLNK) has been Downgraded to Underperform from Neutral by BofA/Merrill in its latest research note that was published on January 03. Stifel analysts have downgraded their rating of NLNK stock from Buy to Hold in a separate flash note to investors on August 01. Analysts at Robert W. Baird downgraded the stock to a Neutral call from its previous Outperform stance, in a research note that dated back to April 09.
NewLink’s stock is covered by 1 analysts, with none of them rating the stock as Buy. It has been deemed to have strong buy by none of the analysts, 1 of them have rated it as a Hold while none of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only none analysts. none of them rated it as strong buy with 1 of them recommended investors to Hold on to the stock. Meanwhile, 1 analyst(s) rated it as a sell. The above data shows that NLNK has an average analyst rating of 3.00.
NewLink Genetics Corporation, which has current market capitalization of above $59 Million, published its last quarter earnings on June 30, 2019. The company was able to amass $0.11 million in revenue. This figure is $0.01 million more than what analysts had expected which was $0.1 million.
NLNK surged by $0.02 during the normal trading session on Monday and reaching a high of $1.61 during the day while it closed the day at $1.53. The NewLink stock had a low trading volume of 0.33 million shares on that day, which is low compared to the average daily volume of 385.69M shares. NLNK has also lost 7.27% of its value over the past 7 days. However, the stock has declined by 4.38% in the 3 months of the year. Over the past six months meanwhile, it has gained 3.38% while it has added 0.66% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -20.31% from its 3 months high price. However, taking another look at NLNK will indicate that it is trading +12.5% away from its 90-day low. Looking at the bigger picture, the NewLink Genetics Corporation stock has dropped by -52.34% from its 52-week high while it has surged by +19.53% from its 52-week low price.
NewLink has around 105 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $9 Billion. The NewLink stock is bringing in revenue of over 12 months, which is roughly 151 Million. Despite all that, NewLink Genetics Corporation is seeing things declining very much as their y-o-y quarterly revenue dropped by -93.29%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 30.36%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 30.36%. Over the past 20 days, NewLink’s Stochastic %K stood at 41.07% while its Stochastic %D was revealed to be 48.21%.